Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women

P. L. Selby, H. H G Mcgarrigle, Munro Peacock

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

We compared the effect of administering oestradiol via the transdermal or oral routes in six and eight postmenopausal women respectively. Although both treatments achieved similar plasma levels of oestradiol, oral administration led to much greater increases in plasma levels of oestrone and the sulphates and glucuronides of oestradiol, oestrone and oestriol than transdermal treatment (P <0.001). Both treatments reduced plasma FSH; from 42 ± 10 (SE) IU/l to 30 ± 2 IU/l with oral and from 46 ± 7 IU/l to 28 ± 6 IU/l with transdermal treatment. Urine calcium excretion fell from 0.41 ± 0.06 (molar ratio to creatinine) to 0.17 ± 0.02 with oral and from 0.25 ± 0.06 to 0.13 ± 0.02 with transdermal treatment. Patients' symptoms were improved by both treatments. These changes were related to the plasma oestradiol concentration but not to that of oestrone. Oral, but not transdermal, treatment stimulated hepatic protein synthesis as shown by increased plasma levels of both vitamin-D-binding globulin and sex-hormone-binding globulin. We conclude that although both oral and transdermal oestradiol reduce postmenopausal bone loss, gonadotropin secretion and symptoms, oral treatment also leads to hepatic stimulation and extensive metabolism of oestradiol, both of which may increase side-effects without conferring additional benefit.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalClinical Endocrinology
Volume30
Issue number3
StatePublished - 1989
Externally publishedYes

Fingerprint

Cutaneous Administration
Bone Remodeling
Gonadotropins
Estradiol
Estrogens
Proteins
Estrone
Therapeutics
Vitamin D-Binding Protein
Sex Hormone-Binding Globulin
Estriol
Postmenopausal Osteoporosis
Liver
Glucuronides
Oral Administration
Creatinine
Urine
Calcium

ASJC Scopus subject areas

  • Endocrinology

Cite this

@article{75379952ca4e4d4fa0f09a981f392cc8,
title = "Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women",
abstract = "We compared the effect of administering oestradiol via the transdermal or oral routes in six and eight postmenopausal women respectively. Although both treatments achieved similar plasma levels of oestradiol, oral administration led to much greater increases in plasma levels of oestrone and the sulphates and glucuronides of oestradiol, oestrone and oestriol than transdermal treatment (P <0.001). Both treatments reduced plasma FSH; from 42 ± 10 (SE) IU/l to 30 ± 2 IU/l with oral and from 46 ± 7 IU/l to 28 ± 6 IU/l with transdermal treatment. Urine calcium excretion fell from 0.41 ± 0.06 (molar ratio to creatinine) to 0.17 ± 0.02 with oral and from 0.25 ± 0.06 to 0.13 ± 0.02 with transdermal treatment. Patients' symptoms were improved by both treatments. These changes were related to the plasma oestradiol concentration but not to that of oestrone. Oral, but not transdermal, treatment stimulated hepatic protein synthesis as shown by increased plasma levels of both vitamin-D-binding globulin and sex-hormone-binding globulin. We conclude that although both oral and transdermal oestradiol reduce postmenopausal bone loss, gonadotropin secretion and symptoms, oral treatment also leads to hepatic stimulation and extensive metabolism of oestradiol, both of which may increase side-effects without conferring additional benefit.",
author = "Selby, {P. L.} and Mcgarrigle, {H. H G} and Munro Peacock",
year = "1989",
language = "English (US)",
volume = "30",
pages = "241--249",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women

AU - Selby, P. L.

AU - Mcgarrigle, H. H G

AU - Peacock, Munro

PY - 1989

Y1 - 1989

N2 - We compared the effect of administering oestradiol via the transdermal or oral routes in six and eight postmenopausal women respectively. Although both treatments achieved similar plasma levels of oestradiol, oral administration led to much greater increases in plasma levels of oestrone and the sulphates and glucuronides of oestradiol, oestrone and oestriol than transdermal treatment (P <0.001). Both treatments reduced plasma FSH; from 42 ± 10 (SE) IU/l to 30 ± 2 IU/l with oral and from 46 ± 7 IU/l to 28 ± 6 IU/l with transdermal treatment. Urine calcium excretion fell from 0.41 ± 0.06 (molar ratio to creatinine) to 0.17 ± 0.02 with oral and from 0.25 ± 0.06 to 0.13 ± 0.02 with transdermal treatment. Patients' symptoms were improved by both treatments. These changes were related to the plasma oestradiol concentration but not to that of oestrone. Oral, but not transdermal, treatment stimulated hepatic protein synthesis as shown by increased plasma levels of both vitamin-D-binding globulin and sex-hormone-binding globulin. We conclude that although both oral and transdermal oestradiol reduce postmenopausal bone loss, gonadotropin secretion and symptoms, oral treatment also leads to hepatic stimulation and extensive metabolism of oestradiol, both of which may increase side-effects without conferring additional benefit.

AB - We compared the effect of administering oestradiol via the transdermal or oral routes in six and eight postmenopausal women respectively. Although both treatments achieved similar plasma levels of oestradiol, oral administration led to much greater increases in plasma levels of oestrone and the sulphates and glucuronides of oestradiol, oestrone and oestriol than transdermal treatment (P <0.001). Both treatments reduced plasma FSH; from 42 ± 10 (SE) IU/l to 30 ± 2 IU/l with oral and from 46 ± 7 IU/l to 28 ± 6 IU/l with transdermal treatment. Urine calcium excretion fell from 0.41 ± 0.06 (molar ratio to creatinine) to 0.17 ± 0.02 with oral and from 0.25 ± 0.06 to 0.13 ± 0.02 with transdermal treatment. Patients' symptoms were improved by both treatments. These changes were related to the plasma oestradiol concentration but not to that of oestrone. Oral, but not transdermal, treatment stimulated hepatic protein synthesis as shown by increased plasma levels of both vitamin-D-binding globulin and sex-hormone-binding globulin. We conclude that although both oral and transdermal oestradiol reduce postmenopausal bone loss, gonadotropin secretion and symptoms, oral treatment also leads to hepatic stimulation and extensive metabolism of oestradiol, both of which may increase side-effects without conferring additional benefit.

UR - http://www.scopus.com/inward/record.url?scp=0024593620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024593620&partnerID=8YFLogxK

M3 - Article

C2 - 2512035

AN - SCOPUS:0024593620

VL - 30

SP - 241

EP - 249

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -